Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- "Forgotten axis" between plant substances, gut and systemic health
Microbiome and phytotherapy
- HIV: updated EACS guideline
Individualized approach to sustainable prevention and care
- Evidence-based diagnostics and treatment in the medical setting
Anxiety and depression disorders in adolescence
- Neuroenhancement
Can you swallow intelligence? Relevant substance classes times for healthy people
- Microbiome, inflammaging and affective/cognitive health
Gut-brain axis in old age
- Vitiligo - the level of suffering should not be underestimated
A lot can be achieved therapeutically nowadays
- Vector-borne infections with skin manifestations
Arboviruses and leishmaniasis in Europe
- Patient-centered rounds in medicine